[go: up one dir, main page]

MX2019002198A - Composiciones solubles en agua que comprenden cannabinoides purificadas. - Google Patents

Composiciones solubles en agua que comprenden cannabinoides purificadas.

Info

Publication number
MX2019002198A
MX2019002198A MX2019002198A MX2019002198A MX2019002198A MX 2019002198 A MX2019002198 A MX 2019002198A MX 2019002198 A MX2019002198 A MX 2019002198A MX 2019002198 A MX2019002198 A MX 2019002198A MX 2019002198 A MX2019002198 A MX 2019002198A
Authority
MX
Mexico
Prior art keywords
water soluble
soluble compositions
purified cannabinoids
compositions
purified
Prior art date
Application number
MX2019002198A
Other languages
English (en)
Other versions
MX380850B (es
Inventor
Aron Levy Kurt
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of MX2019002198A publication Critical patent/MX2019002198A/es
Publication of MX380850B publication Critical patent/MX380850B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Estas divulgaciones se refieren a nuevas composiciones y métodos para la generación de formulaciones cannabinoides. En una modalidad, la divulgación proporciona composiciones solubles en agua que comprenden un primer cannabinoide purificado y la vitamina E TPGS. En una modalidad, la descripción en el presente documento comprende un método de fabricación de polvos que comprenden material de calefacción a una primera temperatura y una segunda temperatura.
MX2019002198A 2016-08-29 2017-08-29 Composiciones solubles en agua que comprenden cannabinoides purificadas MX380850B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380954P 2016-08-29 2016-08-29
PCT/US2017/049219 WO2018044953A1 (en) 2016-08-29 2017-08-29 Water soluble compositions comprising purified cannabinoids

Publications (2)

Publication Number Publication Date
MX2019002198A true MX2019002198A (es) 2019-08-16
MX380850B MX380850B (es) 2025-03-12

Family

ID=61301487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002198A MX380850B (es) 2016-08-29 2017-08-29 Composiciones solubles en agua que comprenden cannabinoides purificadas

Country Status (10)

Country Link
US (6) US10568865B2 (es)
EP (1) EP3503875B1 (es)
CN (1) CN110177543A (es)
AU (1) AU2017319320B2 (es)
BR (1) BR112019003815A2 (es)
CA (1) CA3034004C (es)
CL (1) CL2019000474A1 (es)
CO (1) CO2019002744A2 (es)
MX (1) MX380850B (es)
WO (1) WO2018044953A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017319320B2 (en) 2016-08-29 2023-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
US11395842B2 (en) * 2017-12-29 2022-07-26 Buzzelet Development And Technologies Ltd Purified cannabis extracts and methods for production thereof
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
SG11202010006UA (en) 2018-04-09 2020-11-27 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019211771A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Water soluble and water dispersible formulations of cannabinoids
EP3911148A4 (en) * 2019-01-17 2022-10-12 Synthonics, Inc. SOLID MICELLAR COMPOSITIONS OF CANNABINOID ACIDS
US10993928B2 (en) * 2019-04-26 2021-05-04 Natural Extraction Systems, LLC Compositions comprising non-crystalline forms of cannabidiol
US10780075B1 (en) * 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
KR20220045167A (ko) * 2019-08-10 2022-04-12 로커스 아이피 컴퍼니 엘엘씨 일반 의약품 및 의약품의 생체이용률을 증가시키는 방법
KR20220064376A (ko) * 2019-09-18 2022-05-18 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 흡입에 의한 전달을 위한 칸나비노이드의 조성물
US11186944B1 (en) * 2019-10-23 2021-11-30 Sam Salem And Son, Llc Method of making polyester fabric treated with a CBD powder
CN112915121A (zh) * 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
CA3166011A1 (en) 2019-12-31 2021-07-08 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
CA3078970A1 (en) * 2020-04-16 2021-10-16 National Research Council Of Canada Water soluble formulations containing cannabinoids
CN114748429A (zh) 2020-12-29 2022-07-15 汉义生物科技（北京）有限公司 一种水溶性大麻素制剂及其制备方法
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2022254425A1 (en) * 2021-05-31 2022-12-08 Cannabotech Ltd. Compositions comprising a cannabinoid and uses thereof
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
US20250170152A1 (en) * 2022-02-28 2025-05-29 Emyria Cannabinoid Dosage Form
DE202022102593U1 (de) 2022-05-12 2022-05-30 DÖHLER GmbH Zusammensetzung mit Cannabinoiden und deren Verwendung

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837228A (en) 1979-05-31 1989-06-06 The University Of Mississippi Antiinflammatory and antimicrobial compounds and compositions
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20030101902A1 (en) 2001-12-04 2003-06-05 Ann Reitnauer Hot melt inks
EP1539069A4 (en) 2002-05-31 2007-11-14 Univ Mississippi TRANSMUCOSAL DELIVERY OF CANNABINOIDS
WO2005046363A2 (en) 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
FR2885619B1 (fr) 2005-05-13 2011-02-11 Imaje Sa Composition d'encre liquide, alimentaire, ingerable pour l'impression par jet d'encre
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US20090098192A1 (en) 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
DE102009019322A1 (de) 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
HRP20171236T1 (hr) 2009-08-31 2017-10-20 Zynerba Pharmaceuticals, Inc. Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
WO2011135591A2 (en) 2010-04-29 2011-11-03 Shasun Pharmaceuticals Limited Novel tablet composition of polyallylamine polymers
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2013050419A1 (en) 2011-10-06 2013-04-11 Novartis Ag Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
JP6069522B2 (ja) 2013-03-29 2017-02-01 インターコンチネンタル グレート ブランズ エルエルシー 透明及び半透明の液体充填キャンディ；その製造方法；無糖液体可食組成物；及びその使用
US9056049B2 (en) 2013-05-30 2015-06-16 Chin Yuan Huang Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
CN105873566B (zh) 2013-10-29 2019-06-07 艾克制药有限公司 含有δ9-四氢大麻酚的压制片剂、其制造方法及此类片剂在口服治疗中的用途
JP2016537412A (ja) * 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US9861611B2 (en) * 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US20190125779A1 (en) 2014-12-30 2019-05-02 University Of Houston System Pharmaceutical compositions
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
US20170266153A1 (en) 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
AU2017319320B2 (en) 2016-08-29 2023-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
WO2018142403A1 (en) 2017-02-02 2018-08-09 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
BR112020004772A2 (pt) 2017-09-28 2020-09-24 Canopy Growth Corporation composições comestíveis de canabinoides
EP3813823A4 (en) 2018-06-28 2022-08-10 Canopy Growth Corporation Compositions and methods for agonizing the cb2 receptor

Also Published As

Publication number Publication date
MX380850B (es) 2025-03-12
US20210000791A1 (en) 2021-01-07
EP3503875A1 (en) 2019-07-03
AU2017319320A1 (en) 2019-04-04
US20190183853A1 (en) 2019-06-20
CL2019000474A1 (es) 2019-05-10
BR112019003815A2 (pt) 2019-05-21
AU2017319320B2 (en) 2023-08-03
US20200253924A1 (en) 2020-08-13
EP3503875A4 (en) 2020-06-24
US12285405B2 (en) 2025-04-29
CA3034004A1 (en) 2018-03-08
WO2018044953A1 (en) 2018-03-08
CN110177543A (zh) 2019-08-27
CO2019002744A2 (es) 2019-04-12
US10568865B2 (en) 2020-02-25
US20200121637A1 (en) 2020-04-23
US20210308097A1 (en) 2021-10-07
US10722490B2 (en) 2020-07-28
US12324801B2 (en) 2025-06-10
CA3034004C (en) 2021-08-03
US20210308098A1 (en) 2021-10-07
US11510897B2 (en) 2022-11-29
EP3503875B1 (en) 2025-09-17
US10842773B2 (en) 2020-11-24
EP3503875C0 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
CO2019002744A2 (es) Composiciones solubles en agua que comprenden cannabinoides purificadas
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2016015636A (es) Formulaciones cannabinoides estables.
CO2018008847A2 (es) Formulaciones líquidas inhibidoras de ureasa
MX2017001628A (es) Formulacion que comprende particulas.
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX2015008983A (es) Pelicula comestible soluble en agua.
CO2018008304A2 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
CL2017002694A1 (es) Métodos para mejora hidráulica de cultivos
AR105894A1 (es) Composición para aplicación tópica que comprende dimetil isosorbida, un poliol, y un antioxidante fenólico o polifenólico
CL2021000310A1 (es) Composiciones de curcuminoides
CL2017003091A1 (es) Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
CL2019000887A1 (es) Extracto de planta impregnado de alulosa y método de preparación para el mismo.
AR095669A1 (es) Toxinas, composiciones y métodos relacionados
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
MX383816B (es) Metodo para producir polvo hidraulico.
CL2018002946A1 (es) Métodos para elaborar formulaciones nutricionales.
CO2017003989A2 (es) Composición herbicida y proceso para prepararla
NI201800105A (es) Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos.
CL2016001008A1 (es) Formulaciones de inyección con base en aceite de sésamo.